Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Using Deep Brain Stimulation to Treat Alzheimer Disease Symptoms
February 1st 2023Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.
Antiseizure Agent EQU-001 Shows Safety, Tolerability, and Preliminary Efficacy in Phase 2 Study
January 31st 2023In addition to showing a tolerable safety profile, EQU-001 resulted in reduced IL-17 and IL-1b plasma levels relative to baseline and limited the ability of peripheral mononuclear cells to secrete additional pro-inflammatory cytokines.
International Panel of Experts Proposes New Diagnostic Criteria for MOG Antibody Associated Disease
January 26th 2023The new criteria, inclusive of both pediatric and adult patients, advocates for testing for MOG-IgG in appropriate populations, and cautions against testing patients with clinical and radiological features typical of multiple sclerosis.
Argentinean-Based Study Highlights International Barriers to Access and Utilization of NMOSD Care
January 26th 2023Data showed that slightly more than half of the patients with NMOSD visited at least 2 neurologists before receiving full diagnosis, and less than 30% reported they were aware of at least 1 nearby specialized NMOSD center.
Cognitive Impairments in Activities of Daily Living Predict Conversion to Parkinson Disease Dementia
January 26th 2023After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.
Mesdopetam Fails to Improve ON Time But Shows Anti-Dyskinesia Effects in Parkinson Disease
January 25th 2023Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.
FDA Accepts Supplemental NDA for Valbenazine as Therapy for Huntington Disease Chorea
January 24th 2023The phase 3 KINECT-HD study, which showed statistically significant differences from placebo in Total Maximal Chorea score, served as one of the main parts to valbenazine’s supplemental new drug application.
Growing Brivaracetam’s Potential Through the Adaptive, Dose-Finding EXPAND Study
January 22nd 2023The trial’s 2-stage design seeks to answer questions about the dosing and efficacy of brivaracetam, a previously approved agent for partial-onset seizures in patients with childhood absence epilepsy and juvenile absence epilepsy.
Real-World Data of Spinal Muscular Atrophy Shows High Adherence to Nusinersen Dosing Regimen
January 20th 2023Nearly 94% of nusinersen doses recorded in electronic health records database and more than 80% of doses recorded in the claims databases were received on time according to the recommended dosing schedule.
Ticagrelor and Aspirin Combination Most Effective in CYP2C19 Carriers With Low Risk Profile
January 19th 2023The study provided class II evidence that CYP2C19 loss of function carriers with minor stroke or transient ischemic attack at low risk, but not high risk, of recurrent stroke received greater benefit from ticagrelor and aspirin rather than clopidogrel and aspirin.